Skip to content

Impact of the COVID-19 Pandemic on Vaccination

Impact of the COVID-19 Pandemic on Vaccination in Patients at Risk of Infection

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04657263
Acronym
COVIDVacImpac
Enrollment
500
Registered
2020-12-08
Start date
2020-11-01
Completion date
2021-05-30
Last updated
2021-10-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19

Keywords

People over 18 years old, vaccines, immunization schedule, Infection

Brief summary

The vaccination policy is drawn up in France by the French Minister of Health, who makes public the vaccination schedule after the opinion of the High Authority of Health. Currently according to the 2019 immunization schedule, the dTP vaccine is the only mandatory in the general population with recalls in adults aged 25, 45, 65 and every 10 years. In 2011, the Ministry of Health estimated that only 50.5% of the general population was up to date against dTP. Two vaccines are recommended for person at risk of infection according to the current vaccine schedule: the flu vaccine and the pneumococcal vaccine. In fact, influenza and pneumococcal disease are more frequent and more serious in patients with chronic diseases (diabetes, cardiac insufficiency..) compared to the general population. The vaccination coverage rate of at-risk populations is dramatically below the vaccination coverage targets set by the Ministry of Health. Indeed, there are many barriers to vaccination, medical and para-medical barriers, but also individual barriers. The current COVID-19 pandemic has identified people at risk of severe infection and death risk, particularly those with co-morbidities (diabetes, cardiovascular disease, etc.). Thus, this pandemic may have contributed to change in patients' perceptions regarding both the risk of infection and the potential interest and benefit of vaccination.

Interventions

Vaccine coverage assessment

Sponsors

University Hospital, Montpellier
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Person at risk of infection according to french 2019 immunization schedule * Patients aged above 18 years old

Exclusion criteria

\- Patient \< 18 years

Design outcomes

Primary

MeasureTime frameDescription
number of persons at risk of infection up to date with their mandatory and recommended vaccinations during COVID19 pandemic1 daynumber of persons at risk of infection up to date with their mandatory and recommended vaccinations during COVID19 pandemic

Secondary

MeasureTime frameDescription
Number of persons at risk of infection accepting COVID19 vaccination1 dayNumber of persons at risk of infection accepting COVID19 vaccination

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026